6XX2
| |
6MX9
| Lysozyme bound to 3-Aminophenol | Descriptor: | 1,2-ETHANEDIOL, 3-aminophenol, BENZAMIDINE, ... | Authors: | Blackburn, A, Partowmah, S.H, Brennan, H.M, Mestizo, K.E, Stivala, C.D, Petreczky, J, Perez, A, Horn, A, McSweeney, S. | Deposit date: | 2018-10-30 | Release date: | 2018-12-26 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | A simple technique to improve microcrystals using gel exclusion of nucleation inducing elements To Be Published
|
|
6XX7
| Arabidopsis thaliana Casein Kinase 2 (CK2) alpha-1 crystal in complex with ANP | Descriptor: | CHLORIDE ION, Casein kinase II subunit alpha-1, MAGNESIUM ION, ... | Authors: | Demulder, M, De Veylder, L, Loris, R. | Deposit date: | 2020-01-27 | Release date: | 2020-04-15 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Crystal structure of Arabidopsis thaliana casein kinase 2 alpha 1. Acta Crystallogr.,Sect.F, 76, 2020
|
|
6N6Q
| |
5YEF
| Crystal structure of CTCF ZFs2-8-Hs5-1aE | Descriptor: | DNA (27-MER), Transcriptional repressor CTCF, ZINC ION | Authors: | Yin, M, Wang, J, Wang, M, Li, X, Wang, Y. | Deposit date: | 2017-09-17 | Release date: | 2017-11-29 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.807 Å) | Cite: | Molecular mechanism of directional CTCF recognition of a diverse range of genomic sites Cell Res., 27, 2017
|
|
5YF9
| Crystal structure of CK2a2 form-2 | Descriptor: | Casein kinase II subunit alpha', NICOTINIC ACID, SULFATE ION | Authors: | Tsuyuguchi, M, Kinoshita, T. | Deposit date: | 2017-09-20 | Release date: | 2018-05-16 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (1.89 Å) | Cite: | Crystal structures of human CK2 alpha 2 in new crystal forms arising from a subtle difference in salt concentration Acta Crystallogr F Struct Biol Commun, 74, 2018
|
|
6N02
| CO-bound Sperm Whale Myoglobin, room temperature structure, first 2 degrees of 5 degree total oscillation | Descriptor: | CARBON MONOXIDE, Myoglobin, CO-bound, ... | Authors: | Finke, A.D, Wierman, J.L, Pare-Labrosse, O, Sarrachini, A, Besaw, J, Mehrabi, P, Gruner, S.M, Miller, R.J.D. | Deposit date: | 2018-11-06 | Release date: | 2019-03-27 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Fixed-target serial oscillation crystallography at room temperature. IUCrJ, 6, 2019
|
|
6XVR
| Human myelin protein P2 mutant L35S | Descriptor: | Myelin P2 protein, PALMITIC ACID, SULFATE ION | Authors: | Ruskamo, S, Lehtimaki, M, Kursula, P. | Deposit date: | 2020-01-22 | Release date: | 2020-04-08 | Last modified: | 2024-01-24 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Cryo-EM, X-ray diffraction, and atomistic simulations reveal determinants for the formation of a supramolecular myelin-like proteolipid lattice. J.Biol.Chem., 295, 2020
|
|
5YJ9
| Crystal structure of Tribolium castaneum PINK1 kinase domain in complex with AMP-PNP | Descriptor: | MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER, Serine/threonine-protein kinase PINK1, ... | Authors: | Okatsu, K, Sato, Y, Fukai, S. | Deposit date: | 2017-10-09 | Release date: | 2018-07-25 | Method: | X-RAY DIFFRACTION (2.53 Å) | Cite: | Structural insights into ubiquitin phosphorylation by PINK1. Sci Rep, 8, 2018
|
|
8EML
| Crystal Structure of Gsx2 Homeodomain in Complex with DNA | Descriptor: | DNA (5'-D(P*GP*AP*GP*CP*TP*AP*AP*TP*TP*AP*AP*AP*GP*C)-3'), DNA (5'-D(P*GP*CP*TP*TP*TP*AP*AP*TP*TP*AP*GP*CP*TP*C)-3'), GS homeobox 2, ... | Authors: | Webb, J.A, Kovall, R.A. | Deposit date: | 2022-09-28 | Release date: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.21 Å) | Cite: | Crystal Structure of Gsx2 Homeodomain in Complex with DNA To Be Published
|
|
8YA1
| HEN EGG WHITE LYSOZYME | Descriptor: | Lysozyme C | Authors: | Zhang, C.Y, Xu, Q, Wang, W.W, Zhou, H. | Deposit date: | 2024-02-07 | Release date: | 2024-02-28 | Method: | X-RAY DIFFRACTION (1.57 Å) | Cite: | Crystallographic data collection using a multilayer monochromator on an undulator beamline at SSRF To Be Published
|
|
8YBG
| |
6N3N
| Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents | Descriptor: | N-{3-[(2-aminopyrimidin-5-yl)ethynyl]-2,4-difluorophenyl}-2,5-dichloro-3-(hydroxymethyl)benzene-1-sulfonamide, eIF-2-alpha kinase GCN2,eIF-2-alpha kinase GCN2 | Authors: | Hoffman, I.D, Fujimoto, J, Kurasawa, O, Takagi, T, Klein, M.G, Kefala, G, Ding, S.C, Cary, D.R, Mizojiri, R. | Deposit date: | 2018-11-15 | Release date: | 2019-10-09 | Last modified: | 2024-03-13 | Method: | X-RAY DIFFRACTION (3.01 Å) | Cite: | Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. Acs Med.Chem.Lett., 10, 2019
|
|
5YJM
| Human chymase in complex with 7-oxo-3-(phenoxyimino)-1,4-diazepane derivative | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-amino-4-((R)-1-((R,Z)-6-(5-chloro-2-methoxybenzyl)-7-oxo-3-(phenoxyimino)-1,4-diazepane-1-carboxamido)propyl)benzoic acid, ZINC ION, ... | Authors: | Sugawara, H. | Deposit date: | 2017-10-11 | Release date: | 2017-12-27 | Last modified: | 2020-07-29 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Structure-based design, synthesis, and binding mode analysis of novel and potent chymase inhibitors Bioorg. Med. Chem. Lett., 28, 2018
|
|
8ENJ
| |
5YID
| Crystal Structure of KNI-10395 bound Plasmepsin II (PMII) from Plasmodium falciparum | Descriptor: | (4R)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-3-[(2S,3S)-2-hydroxy-3-{[S-methyl-N-(phenylacetyl)-L-cysteinyl]amino}-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide, 3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE, Plasmepsin II, ... | Authors: | Mishra, V, Rathore, I, Bhaumik, P. | Deposit date: | 2017-10-04 | Release date: | 2018-07-11 | Last modified: | 2019-05-29 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights. Febs J., 285, 2018
|
|
6N48
| Structure of beta2 adrenergic receptor bound to BI167107, Nanobody 6B9, and a positive allosteric modulator | Descriptor: | (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate, 8-[(1R)-2-{[1,1-dimethyl-2-(2-methylphenyl)ethyl]amino}-1-hydroxyethyl]-5-hydroxy-2H-1,4-benzoxazin-3(4H)-one, Camelid Antibody Fragment, ... | Authors: | Liu, X, Masoudi, A, Kahsai, A.W, Huang, L.Y, Pani, B, Hirata, K, Ahn, S, Lefkowitz, R.J, Kobilka, B.K. | Deposit date: | 2018-11-17 | Release date: | 2019-06-26 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (3.2 Å) | Cite: | Mechanism of beta2AR regulation by an intracellular positive allosteric modulator. Science, 364, 2019
|
|
5YKW
| Structural basis of the thiol resolving mechanism in yeast mitochondrial 1-Cys peroxiredoxin via glutathione/thioredoxin systems | Descriptor: | Thioredoxin-3, mitochondrial, peptide THR-PRO-VAL-CYS-THR-THR-GLU-VAL | Authors: | Li, C.C, Yang, J, Yang, M.J, Liu, L, Peng, C.T, Li, T, He, L.H, Song, Y.J, Zhu, Y.B, Zhao, N.L, Zhao, C, Bao, R. | Deposit date: | 2017-10-16 | Release date: | 2018-10-24 | Last modified: | 2019-11-06 | Method: | X-RAY DIFFRACTION (2.08 Å) | Cite: | Structural basis of the thiol resolving mechanism in yeast mitochondrial 1-Cys peroxiredoxin via glutathione/thioredoxin systems to be published
|
|
8ERN
| Cyclin-free CDK2 in complex with Cpd21 | Descriptor: | Cyclin-dependent kinase 2, GLYCEROL, N,3-dimethyl-4-({7-[(2S)-2-methylpyrrolidine-1-carbonyl]quinazolin-2-yl}amino)benzene-1-sulfonamide | Authors: | Murray, J.M, Oh, A. | Deposit date: | 2022-10-12 | Release date: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.64 Å) | Cite: | Cyclin-free CDK2 in complex with Cpd21 To Be Published
|
|
8YA4
| |
6MQG
| |
8OIL
| |
8YBH
| |
8Y9W
| |
8OZ3
| Crystal structure of scFv ATOR 1017 bound to human 4-1BB | Descriptor: | Single chain Fv, Tumor necrosis factor receptor superfamily member 9 | Authors: | Hakansson, M, Von Schantz, L, Rose, N. | Deposit date: | 2023-05-08 | Release date: | 2024-03-13 | Method: | X-RAY DIFFRACTION (3.1 Å) | Cite: | ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1. Cancer Immunol.Immunother., 72, 2023
|
|